Mileutis, an innovative biopharmaceutical firm based in Israel and focused on reforming the way farmers and veterinarians address a variety of diseases, announced that its CEO and co-founder, David Javier Iscovich, will be presenting at the Stifel 2023 Jaws & Paws Conference in New York City today, May 31st, 2023.
Iscovich’s presentation will encompass Mileutis’ game-changing solutions, emphasizing the company’s commitment to effecting positive transformations in the industry. The spotlight will be on Mileutis’ Imilac™, a residue-free intramammary solution for managing, treating, and preventing bovine mastitis at dry-off.
Established in 2004, Mileutis is spearheaded by David Javier Iscovich, with the R&D initiative directed by Dr. Jose Iscovich, president and co-founder of the company.
Mastitis is the most common disease in dairy herds worldwide and the most expensive to treat. The novel residue-free peptide Imilac™, developed by Mileutis, is the first in a series of patented products addressing the growing concern over antibiotic resistance and excessive use of antibiotics in the global dairy industry. Mileutis’ leading-edge products are projected to potentially generate annual revenues exceeding $1 billion worldwide.
